Another promising approach, DEN-181 immunotherapy, introduces liposomal technology to inject collagen II as a liposome-encapsulated antigen together with calcitriol in patients with ACPA-positive RA. The gene discussed is PRTN3; the disease is rheumatoid arthritis.